Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "futcoin fc 26 Besuche die Website Buyfc26coins.com. Kein Stress, super..8Yet"

Looking for quality documents?
external link icon
Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors. Dr. Mhatre brings to the director role over 25 years of relevant experience, which includes his current position as Senior Vice President, Product and Technology Development for Biogen Inc., a leading multinational biopharmaceutical company. Dr. Mhatre leads a cross-functional department responsible for product and process development, process analytics and small-scale manufacturing. Most recently, he has also led the Engineering and Manufacturing Science departments. Throughout his career, he has evaluated and implemented cutting-edge production platforms and process analytical tools for a diverse array of therapeutics, including monoclonal antibodies, gene therapies and oligonucleotides, as well as small molecules.

“We are delighted to welcome Dr. Mhatre to our board,” said
external link icon
Repligen Announces Market Launch of OPUS® 80R, Reinforces Technology Leadership in Pre-Packed Chromatography
- First and only available 80 cm diameter pre-packed column to address large-scale clinical and commercial-scale manufacturing of biological drugs -
WALTHAM, Mass., March 20, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its next-generation OPUS® column, the OPUS 80R, which is the largest pre-packed column on the market and is suitable for late-stage clinical into commercial-scale manufacturing of biological drugs. OPUS columns are used in downstream manufacturing processes, to purify biologics including monoclonal antibodies, recombinant proteins, vaccines and gene therapies. The OPUS product line is the industry’s broadest and most scalable with packed bed volumes now ranging from 50 microliters to 150 liters. The groundbreaking OPUS 80R columns are being highlighted in a Technology Workshop on March 21 st at the BioProcess International West
external link icon
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 in shares of its common stock in connection with the proposed public offering. All shares of common stock will be offered by Repligen Corporation. Repligen Corporation expects to use the net proceeds to fund the cash portion of the purchase price for its previously announced proposed acquisition of C Technologies, Inc. and for working capital and other general corporate purposes. J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering. Janney Montgomery Scott is acting as lead manager for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the
external link icon
Repligen Reports Third Quarter 2013 Financial Results
- Product Revenue Grows 10% for the Quarter - - Net Income Grows 226% to $5.9 Million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EST - WALTHAM, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for the third quarter ended September 30, 2013. Below are the Company's financial and business highlights for the third quarter, financial guidance for the year and dial-in numbers for today's conference call. Third Quarter 2013 Financial Highlights Bioprocessing product revenue for the third quarter of 2013 was $12.2 million, an increase of approximately10% over the third quarter of 2012.
  Total revenue for the third quarter of 2013 was $18.8 million, an increase of approximately 25% over the third quarter of 2012.
  Bioprocessing product gross profit margin was 53.5% for the third quarter of 2013, compared to 42.3% during the third quarter of 2012.
  Net income increased to $5.9 million
external link icon
Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-year
Raises revenue guidance to $267-$270 million for full year 2019, representing 31%-32% organic growth WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2019. Provided in this press release are financial highlights for the three- and nine-month periods ended September 30, 2019, updated financial guidance for the fiscal year 2019, and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are pleased with our strong performance in the third quarter, reporting over $69 million in revenue and robust organic growth of 28%. Our filtration and chromatography franchises continued to track ahead of expectations and in process analytics, our C
corporate icon
Antibody Drug Conjugates
Antibody-drug conjugates (ADC) represent a breakthrough in targeted cancer therapy, combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. By delivering powerful treatments directly to cancer cells, ADCs provide an alternative solution that enhances efficacy and minimizes side effects.
event icon
Antibody–Drug Conjugate Manufacturing: Driving Process Productivity and Reducing Risk
In this webinar, Field Applications Scientists Zoltán Gulyás and Nigel Herbert discuss how innovative technologies can help ADC manufacturers overcome common process hurdles. Through three real-world case studies, you’ll learn how to: Accelerate processing time and minimize risk to product and operators during tangential flow filtration (TFF) Maintain product consistency and operator safety while minimizing extractables and leachables. Drive process efficiency and reduce turnaround time with accurate, real-time DAR measurement
video icon
Protein Concentration Determination and Automation During Drug Product Dilution Processes Using FlowVPE System
Protein concentration is one of the critical quality attributes of fill-finished drug products, as it ultimately defines the dosage a patient receives. Process analytical tools are key in monitoring this attribute and are used to control the manufacturing process accordingly. This presentation will give an overview of the journey from initial laboratory feasibility tests of the CTech FlowVPE technology to implementation into an aseptic GMP facility for in-process control testing of biologics. In addition, the talk will highlight how the inline technology sheds new light on the manufacturing process and increases product understanding. Building on the availability of real-time continuous protein concentration data, next steps in the development and implementation of a future automated human-free process execution will be shared. Speaker: Raf De Dier, Associate Director Advanced Technology – Janssen.
external link icon
Repligen to Report Third Quarter 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2025 financial results on Tuesday, October 28, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2025. The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of Company’s website. About
external link icon
Repligen to Present at Stifel Nicolaus Healthcare Conference 2012
- Thursday, September 6, 10:20 a.m. EDT - Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will be presenting at the upcoming Stifel Nicolaus Healthcare Conference in Boston. Dr. Herlihy will provide a corporate update and discuss the Company’s recent decision to focus corporate strategy on the growth of its bioprocessing business. The Repligen presentation is scheduled for Thursday, September 6, 2012 at 10:20 a.m. EDT. A live webcast and subsequent archived replay of the presentation will be available through the Investors section of Repligen’s corporate website at www.repligen.com . To access the live webcast, please log on through the Company’s website approximately 15 minutes prior to the presentation. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. Our
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support